lucinactant profile

lucinactant: a pulmonary surfactant composed of sinapultide, colfosceril palmitate, palmitoyloleaoylphosphatidylglycerol, and palmitic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	155886531
MeSH ID	M0487844

Synonym
825600-90-6
lucinactant
l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysine, acetate; sinapultide acetate
B0084-462251

Excerpt	Reference
"Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B."	( Lucinactant for the prevention of respiratory distress syndrome in premature infants. Donn, SM; Jordan, BK, 2013)
"Lucinactant (Surfaxin®) is a new synthetic surfactant with a pulmonary surfactant-associated protein B mimic that recently received FDA approval."	( Lucinactant for the treatment of respiratory distress syndrome in neonates. Fernandez-Bustamante, A; Piehl, E, 2012)
"Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B."	( A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Bernstein, G; d'Agostino, R; Gadzinowski, J; Hajdu, J; Lacaze-Masmonteil, T; Massaro, J; Sanchez-Luna, M; Schaber, CJ; Segal, R; Sinha, SK; Valls i Soler, A; Wiswell, TE, 2005)
"Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. "	( A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Bancalari, A; Bancalari, E; d'Agostino, R; Gadzinowski, J; Kopelman, B; Kornacka, MK; Massaro, J; Merritt, TA; Moya, FR; Salinas, V; Schaber, CJ; Segal, R; Tsai, H, 2005)

Excerpt	Reference
" There were no differences in major dosing complications."	( A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Bernstein, G; d'Agostino, R; Gadzinowski, J; Hajdu, J; Lacaze-Masmonteil, T; Massaro, J; Sanchez-Luna, M; Schaber, CJ; Segal, R; Sinha, SK; Valls i Soler, A; Wiswell, TE, 2005)
" We conducted a masked, multicenter, multinational, randomized, controlled, pilot study to estimate the effects of treating infants at high risk for developing bronchopulmonary dysplasia with lucinactant, a synthetic, peptide-containing surfactant, on safety during dosing and the incidence of death or bronchopulmonary dysplasia."	( A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Aschner, J; Bose, C; Cummings, JJ; Donn, SM; Guardia, C; Laughon, M; Liu, G; Morabito, C; Moya, F; Segal, R, 2009)
" Aerosurf was well tolerated, with transient desaturations observed during dosing without bradycardia or hypotension."	( An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. Bernstein, G; Finer, NN; Job, L; Mazela, J; Merritt, TA; Segal, R, 2010)
" One retreatment was allowed 12-24 hrs after initial dosing if hypoxemia persisted."	( A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Barton, P; Cheifetz, IM; Cruces, P; Guardia, CG; Markovitz, B; Moya, FR; Randolph, AG; Segal, R; Simmons, P; Thomas, NJ, 2012)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (44.12)	29.6817
2010's	18 (52.94)	24.3611
2020's	1 (2.94)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (17.65%)	5.53%
Reviews	11 (32.35%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.08	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
carbamates [no description available]	2.08	1	0	amino-acid anion
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	4.7	3	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.08	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.08	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	5.2	3	1
thiazoles [no description available]	2.08	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
deoxycytidine [no description available]	2.08	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.25	1	0	manganese group element atom
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.08	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	2.08	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination: protein-free, synthetic surfactant containing dipalmitoylphosphatidylcholine, hexadecanol & tyloxapol; used in treatment of respiratory distress syndrome	4.7	3	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.08	1	0	divalent inorganic anion; phosphite ion
colfosceril palmitate colfosceril palmitate: used in the treatment of unilateral pulmonary interstitial emphysema; component of Exosurf. 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine : A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants.	10.2	3	1	1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 32:0	mouse metabolite; surfactant
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.08	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
jtk-303 [no description available]	2.08	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
mirabegron mirabegron: a beta3-adrenergic receptor agonist; structure in first source. mirabegron : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome.	2.08	1	0	1,3-thiazoles; aromatic amide; ethanolamines; monocarboxylic acid amide	beta-adrenergic agonist
avanafil [no description available]	2.08	1	0	aromatic amide; monocarboxylic acid amide; organochlorine compound; prolinols; pyrimidines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
lorcaserin lorcaserin: orally active, small-molecule 5-hydroxytryptamine 2C agonist for the potential treatment of obesity and diabetes. lorcaserin : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group.	2.08	1	0	benzazepine; organochlorine compound	anti-obesity agent; appetite depressant
sinapultide sinapultide: RN & amino acid sequence in first source	3.14	1	0
cobicistat [no description available]	2.08	1	0	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor
quad pill Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination: A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.	2.08	1	0

Condition	Relationship Strength	Studies	Trials
Infantile Respiratory Distress Syndrome [description not available]	10.64	22	4
Respiratory Distress Syndrome, Newborn A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.	10.64	22	4
Bronchopulmonary Dysplasia A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.	8.76	7	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.16	5	0
Aspiration, Meconium [description not available]	3.9	4	0
Meconium Aspiration Syndrome A condition caused by inhalation of MECONIUM into the LUNG of FETUS or NEWBORN, usually due to vigorous respiratory movements during difficult PARTURITION or respiratory system abnormalities. Meconium aspirate may block small airways leading to difficulties in PULMONARY GAS EXCHANGE and ASPIRATION PNEUMONIA.	3.9	4	0
Preterm Birth [description not available]	2.07	1	0
Premature Birth CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).	2.07	1	0
Acute Hypercapnic Respiratory Failure [description not available]	5.7	2	1
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	5.7	2	1
Anoxemia [description not available]	4.37	1	1
Bradyarrhythmia [description not available]	4.37	1	1
Acute Disease Disease having a short and relatively severe course.	4.37	1	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	4.37	1	1
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	4.37	1	1
Lung Injury, Ventilator-Induced [description not available]	2.07	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.07	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.07	1	0
Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.	4.37	2	2
Brain Hemorrhage [description not available]	3.41	1	1
Cystic Periventricular Leukomalacia [description not available]	3.41	1	1
Leukomalacia, Periventricular Degeneration of white matter adjacent to the CEREBRAL VENTRICLES following cerebral hypoxia or BRAIN ISCHEMIA in neonates. The condition primarily affects white matter in the perfusion zone between superficial and deep branches of the MIDDLE CEREBRAL ARTERY. Clinical manifestations include VISION DISORDERS; CEREBRAL PALSY; PARAPLEGIA; SEIZURES; and cognitive disorders. (From Adams et al., Principles of Neurology, 6th ed, p1021; Joynt, Clinical Neurology, 1997, Ch4, pp30-1)	3.41	1	1
Intracranial Hemorrhages Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.	3.41	1	1
Disease, Pulmonary [description not available]	2.94	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2.94	1	0

lucinactant

Description

Cross-References

Synonyms (4)

Research Excerpts

Overview

Dosage Studied

Research

Studies (34)

Study Types